Cargando…

Interstitial lung disease associated to erlotinib treatment: a case report

INTRODUCTION: Few cases of pulmonary toxicity related to epidermal growth factor receptor-targeted agents have been described. CASE PRESENTATION: We report a case of a 63-year-old white male with stage IV non-small cell lung cancer treated with erlotinib who developed a interstitial lung disease. CO...

Descripción completa

Detalles Bibliográficos
Autores principales:	del Castillo, Yolanda, Espinosa, Paulina, Bodí, Fernanda, Alcega, Raquel, Muñoz, Emma, Rabassó, Carlos, Castander, David
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2834622/ https://www.ncbi.nlm.nih.gov/pubmed/20509858 http://dx.doi.org/10.1186/1757-1626-3-59

Ejemplares similares

Successful erlotinib rechallenge after both gefitinib- and erlotinib-induced interstitial lung diseases
por: Arakawa, Nobuhito, et al.
Publicado: (2013)

Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer
por: Makris, Demosthenes, et al.
Publicado: (2007)

Erlotinib Induced Fatal Interstitial Lung Disease in a Patient with Metastatic Non-Small Cell Lung Cancer: Case Report and Review of Literature
por: Mangla, Ankit, et al.
Publicado: (2016)

Erlotinib Achieved Partial Response in a Non-Small Cell Lung Cancer Patient with Gefitinib-Induced Interstitial Lung Disease
por: Tian, Qing, et al.
Publicado: (2011)

Combination Erlotinib-Cisplatin and Atg3-Mediated Autophagy in Erlotinib Resistant Lung Cancer
por: Lee, Jasmine G., et al.
Publicado: (2012)

Fatal Interstitial Lung Disease after Addition of Sorafenib to a Patient with Lung Adenocarcinoma Who Had Failed to Improve with Erlotinib Alone
por: Guan, Yin, et al.
Publicado: (2014)

Review of erlotinib in the treatment of advanced non-small cell lung cancer
por: Ganjoo, Kristen N, et al.
Publicado: (2007)

Erlotinib in the treatment of advanced pancreatic cancer
por: Kelley, Robin K, et al.
Publicado: (2008)

Erlotinib and gefitinib treatments of the lung cancer in an elderly patient result in gastrointestinal bleeding
por: Bai, Hongmei, et al.
Publicado: (2013)

Metformin sensitizes lung cancer cells to treatment by the tyrosine kinase inhibitor erlotinib
por: Wang, Xiaofei, et al.
Publicado: (2017)

HA/HSA co-modified erlotinib–albumin nanoparticles for lung cancer treatment
por: Shen, Yuzhou, et al.
Publicado: (2018)

Identifying erlotinib-sensitive non-small cell lung carcinoma tumors in mice using [(11)C]erlotinib PET
por: Abourbeh, Galith, et al.
Publicado: (2015)

A mixed treatment comparison of Erlotinib vs. placebo and Erlotinib vs. Geftinib using Bayesian approaches
por: Khan, Iftekhar, et al.
Publicado: (2013)

First case report of erlotinib plus ramucirumab treatment for lung carcinosarcoma with EGFR L858R mutation
por: Ishibashi, Naoya, et al.
Publicado: (2023)

Interstitial lung disease in patients with scleroderma - Treatment with rituximab
por: Muñoz, A, et al.
Publicado: (2010)

Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis
por: Zhang, Shu, et al.
Publicado: (2016)

Atypical response to erlotinib in a patient with metastatic lung adenocarcinoma: a case report
por: Sakhri, Linda, et al.
Publicado: (2014)

Black Hairy Tongue Associated with Erlotinib Treatment in a Patient with Advanced Lung Cancer
por: Jeong, Jin Seob, et al.
Publicado: (2011)

Role of erlotinib in the targeted treatment of non-small-cell lung cancer in Chinese patients
por: Li, Wei, et al.
Publicado: (2014)

Prolonged response to first-line erlotinib for advanced lung adenocarcinoma
por: Copeman, Michael
Publicado: (2008)

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
por: Pao, William, et al.
Publicado: (2005)

Erlotinib Resistance in Lung Cancer: Current Progress and Future Perspectives
por: Tang, Joy, et al.
Publicado: (2013)

Acneiform rash during lung cancer therapy with erlotinib (Tarceva(®))
por: Owczarczyk-Saczonek, Agnieszka, et al.
Publicado: (2013)

Efficacy of gefitinib or erlotinib in patients with squamous cell lung cancer
por: Song, Zhengbo, et al.
Publicado: (2013)

The effect of sarcopenia on erlotinib therapy in patients with metastatic lung adenocarcinoma
por: Topcu, Atakan, et al.
Publicado: (2022)

Long-Term Treatment with Erlotinib for EGFR Wild-Type Non-Small Cell Lung Cancer: A Case Report
por: Polychronidou, Genovefa, et al.
Publicado: (2013)

Treatment with gefitinib after erlotinib-induced liver injury: a case report
por: Nakatomi, Katsumi, et al.
Publicado: (2011)

Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer
por: Reguart, Noemí, et al.
Publicado: (2010)

Bowel Perforation after Erlotinib Treatment in a Patient with Non-Small Cell Lung Cancer
por: Cheon, Yun-Hong, et al.
Publicado: (2011)

Circulating free mitochondrial DNA concentration and its association with erlotinib treatment in patients with adenocarcinoma of the lung
por: HUANG, CHU-YUN, et al.
Publicado: (2014)

Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer
por: Schöttle, Jakob, et al.
Publicado: (2015)

Trichomegaly of Eyelashes after Treatment with Erlotinib in Carcinoma Pancreas
por: Goel, Varun, et al.
Publicado: (2014)

Perifollicular Xanthoma Occurring in Patients after Erlotinib Treatment
por: Kim, En Hyung, et al.
Publicado: (2022)

Effects of erlotinib therapy on [(11)C]erlotinib uptake in EGFR mutated, advanced NSCLC
por: Bahce, Idris, et al.
Publicado: (2016)

The combination of HLA-B*15:01 and DRB1*15:01 is associated with gemcitabine plus erlotinib-induced interstitial lung disease in patients with advanced pancreatic cancer
por: Nishimura, Meiko, et al.
Publicado: (2016)

Recovery from paraplegia with administration of erlotinib in a patient with lung adenocarcinoma
por: Kurishima, Koichi, et al.
Publicado: (2014)

IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib
por: Fernando, Romaine I., et al.
Publicado: (2016)

Erlotinib-Loaded Dendrimer Nanocomposites as a Targeted Lung Cancer Chemotherapy
por: Fatani, Wafa K., et al.
Publicado: (2023)

Intrinsic caspase-8 activation mediates sensitization of erlotinib-resistant tumor cells to erlotinib/cell-cycle inhibitors combination treatment
por: Orzáez, M, et al.
Publicado: (2012)

Interstitial lung diseases: course report
por: Kreuter, Michael, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_n0dhd546p71tbv456pj3c0i40d